Literature DB >> 16221226

Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.

Carlo Briguori1, Antonio Colombo, Flavio Airoldi, Nuccia Morici, Giuseppe Massimo Sangiorgi, Anna Violante, Amelia Focaccio, Matteo Montorfano, Mauro Carlino, Gianluigi Condorelli, Bruno Ricciardelli.   

Abstract

BACKGROUND: Recent data support that iodixanol, an iso-osmolality contrast agent, is less nephrotoxic than low-osmolality contrast agents when hydration is the only prophylactic strategy used. We evaluated the nephrotoxicity of iso- and low-osmolality contrast agents with prophylactic administration of N-acetylcysteine (NAC) along with hydration.
METHODS: Two hundred and twenty-five patients with chronic renal insufficiency (serum creatinine >1.5 mg/dL or an estimated glomerular filtration rate <60 mL/min/1.73 m(2)), referred to our institution for coronary and/or peripheral procedures, were assigned to receive low-osmolality (iobitridol group; N = 115) or iso-osmolality (iodixanol group; N = 110) contrast dye. In all cases prophylactic administration of 0.45% saline intravenously and NAC (1200 mg orally twice daily) was used.
RESULTS: Baseline creatinine levels were similar in the 2 groups [iobitridol group = 1.70 (IQR: 1.54-1.98) mg/dL; iodixanol group = 1.73 (IQR: 1.56-2.00) mg/dL, P = 0.33]. The risk score for contrast nephrotoxicity was 5.0 +/- 1.6 in the iobitridol group versus 5.0 +/- 1.8 in the iodixanol group (P = 0.44). Increase of at least 0.5 mg/dL of the creatinine concentration 48 hours after the procedure occurred in 4/115 patients (3.5%) in the iobitridol group and 3/110 patients (2.7%) in the iodixanol group (P = 1.00; OR 0.78; 95% CI 0.17-3.56). Amount of contrast media administration was similar in the 2 groups (iobitridol group = 167 +/- 90 mL; iodixanol group = 164 +/- 82 mL; P = 0.61).
CONCLUSION: Nephrotoxicity of iso-osmolality and low-osmolality contrast agents was similar when a prophylactic strategy of hydration plus NAC was utilized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221226     DOI: 10.1111/j.1523-1755.2005.00683.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography.

Authors:  Ilan Gottlieb; Julie M Miller; Armin Arbab-Zadeh; Marc Dewey; Melvin E Clouse; Leonardo Sara; Hiroyuki Niinuma; David E Bush; Narinder Paul; Andrea L Vavere; John Texter; Jeffery Brinker; João A C Lima; Carlos E Rochitte
Journal:  J Am Coll Cardiol       Date:  2010-02-16       Impact factor: 24.094

Review 2.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

Review 3.  Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2006-05-04       Impact factor: 5.315

Review 4.  Iobitridol: a review of its use as a contrast medium in diagnostic imaging.

Authors:  Paul L McCormack
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

5.  No increased risk for contrast-induced nephropathy after multiple CT perfusion studies of the brain with a nonionic, dimeric, iso-osmolal contrast medium.

Authors:  S Langner; S Stumpe; M Kirsch; M Petrik; N Hosten
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-04       Impact factor: 3.825

6.  Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CT.

Authors:  Martin Zo'o; Marcus Hoermann; Csilla Balassy; Francis Brunelle; Robin Azoulay; Danièle Pariente; Michel Panuel; Patrick Le Dosseur
Journal:  Pediatr Radiol       Date:  2011-06-29

7.  Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol.

Authors:  Euan A Sandilands; Sharon Cameron; Frances Paterson; Sam Donaldson; Lesley Briody; Jane Crowe; Julie Donnelly; Adrian Thompson; Neil R Johnston; Ivor Mackenzie; Neal Uren; Jane Goddard; David J Webb; Ian L Megson; Nicholas Bateman; Michael Eddleston
Journal:  BMC Clin Pharmacol       Date:  2012-02-03

Review 8.  Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review.

Authors:  Maurizio Sessa; Claudia Rossi; Annamaria Mascolo; Cristina Scavone; Gabriella di Mauro; Roberto Grassi; Liberata Sportiello; Salvatore Cappabianca; Concetta Rafaniello
Journal:  Ther Clin Risk Manag       Date:  2017-10-24       Impact factor: 2.423

Review 9.  Renal Safety of Iodinated Contrast Media Depending on Their Osmolarity - Current Outlooks.

Authors:  Bartosz Mruk
Journal:  Pol J Radiol       Date:  2016-04-11

10.  Study of The Effects of N-Acetylcysteine on Oxidative Stress Status of Patients on Maintenance-Hemodialysis Undergoing Cadaveric Kidney Transplantation.

Authors:  Atieh Modarresi; Shadi Ziaie; Jamshid Salamzadeh; Zahra Sahraei; Mohsen Nafar; Yunes Panahi; Mahmoud Parvin; Behzad Einollahi
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.